Camp4 Therapeutics Corp — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Camp4 Therapeutics completed the second closing of its private placement on August 4, 2026, raising $50.1M gross proceeds through issuance of 10.76M common shares at $1.53/share, 39,306 director/employee shares at $1.65, and 21.93M pre-funded warrants at $1.5299 each. The amendment to the original September 9, 2025 securities purchase agreement eliminates future closing tranches, making this the final closing. Investors include Coastlands Capital, Janus Henderson, Balyasny Asset Management, Vivo Capital, 5AM Ventures, Adage Capital, Trails Edge Capital Partners, and CURE SYNGAP1; net proceeds fund advancement of lead program CMP-002 for SYNGAP1-related disorder.
Why this rating
Second tranche of $50.1M equals 343% of company's $14.6M market cap—transformational capital infusion for clinical-stage biotech. Eliminates future dilution uncertainty by finalizing closing structure. Funds Phase 1/2 trial initiation.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.